GlassScriptPhysician profile
Anil Mehta
NPI 1700885092
$3,712.11
in general payments reported to CMS, 2019-2025
27 companies · $876 in 2025
The $876 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $110 · 2021: $344 · 2022: $551 · 2023: $598 · 2024: $736 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.91 |
| Education | $264.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $578.52 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $373.19 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $322.83 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $271.49 | 2019-2025 | Jynarque |
| Amgen INC. | $264.02 | 2019-2025 | Tavneos |
| Vifor Pharma, INC. | $242.04 | 2019-2023 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $236.63 | 2021-2024 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $183.38 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $164.51 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $147.26 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $123.93 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $118.21 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $92.57 | 2019-2025 | Velphoro, Velphoro |
| Horizon Therapeutics Plc | $71.62 | 2020-2023 | Krystexxa |
| Scpharmaceuticals INC. | $56.44 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $56.13 | 2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $55.95 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $51.20 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $49.47 | 2019 | |
| Alexion Pharmaceuticals, INC. | $43.99 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $43.13 | 2019-2022 | |
| Renalytix Ai, INC. | $39.60 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Shire North American Group INC | $36.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.69 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $19.99 | 2023 | Gattex |
| Shield Therapeutics INC | $17.47 | 2023 | Accrufer |
| Genentech USA, INC. | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.